Akero Therapeutics: The Biotech Company Reaches a Significant Turning Point in the Treatment of Liver Diseases
Reading Time: 3 minutes
Akero Therapeutics is a biotechnology company that develops medications for metabolic diseases. The company's leading drug was recently convincing in a study and seems to have a good safety profile, as there were no deaths in the EFX group and the gastrointestinal side effects were manageable. This could be the first therapy of its kind for cirrhosis caused by MASH. Akero Therapeutics (NASDAQ: AKRO) is a clinical-stage biotechnology company focused on developing and commercializing groundbreaking treatments for severe metabolic diseases...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
